Investing.com -- Alto Neuroscience Inc (NYSE:ANRO) stock surged 81% Monday after the company announced a successful FDA meeting that will accelerate development of its treatment-resistant depression ...

Alto Neuroscience  (NYSE:ANRO) has announced that it has secured approximately $50 million in gross proceeds through a ...

Investors reacted positively to news that the company was using a $50 million private placement to help fund a Phase 3 study.

Scientists have discovered that depression can be driven by abnormal sugar modifications on proteins in the brain, offering a new molecular pathway for understanding the disorder.

On Tuesday, Alto Neuroscience, Inc. (NASDAQ:ANRO) announced an asset purchase agreement with Chase Therapeutics Corporation for a portfolio of dopamine agonist drug combinations for ...

Alto Neuroscience, Inc. ( ($ANRO) ) just unveiled an announcement. On October 19, 2025, Alto Neuroscience, Inc. announced a private placement ...

Almost half of people with depression meet criteria for being ‘treatment-resistant’, found a new study published in the British Journal of Psychiatry. Definitions for treatment-resistant depression ...

New research reveals that mental health patients experiencing their first episode of psychosis are more likely to have skin conditions, and that these patients face significantly higher risks of ...

Stress has always been an ugly word, and for good reason. In addition to causing people headaches and sleeplessness, ongoing ...

Alto Neuroscience Highlights Peer-Reviewed Publication of PAX-D Study in The Lancet Psychiatry Demonstrating Robust Clinical Effects of Pramipexole for Patients with Treatment-Resistant Depression – ...